Bioventus LLC, a med-tech company developing orthobiologics, is trying to raise $150 million through an IPO. As is typical of SEC filings when a company plans to go public, Bioventus' filing does note a number of risks it faces in the market. But one not-so-typical risk – which other companies wanting to go public in the future may also have to consider – is Brexit